AbbVie Inc. (NYSE:ABBV) Stock Has Average Price Target of $272.66

Posted by George Bondi on Oct 2nd, 2026

AbbVie Inc. (NYSE:ABBV – Get Free Report) has been given an average rating of “Moderate Buy” by the thirty-one analysts that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $272.66.

Several analysts recently commented on ABBV shares. Oppenheimer raised their price objective on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Wells Fargo & Company upped their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Sanford C. Bernstein reiterated a “market perform” rating and set a $225.00 price target (up from $203.00) on shares of AbbVie in a research report on Tuesday, June 23rd. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Finally, Rothschild & Co Redburn boosted their price target on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th.

Check Out Our Latest Stock Analysis on AbbVie

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Pipeline progress strengthens long-term growth prospects. AbbVie reported positive Phase 2 results for zumilokibart in moderate-to-severe atopic dermatitis, with all tested regimens meeting the primary endpoint. The company selected a mid-dose regimen for Phase 3, supporting the potential to expand its immunology franchise beyond Skyrizi and Rinvoq. AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study
Positive Sentiment: RINVOQ data and a new weight-management candidate add support. Long-term data showed continued repigmentation in non-segmental vitiligo through week 76, while Phase 1 results for ABBV-295 showed favorable tolerability, meaningful weight reduction and a half-life that could support less-frequent dosing. AbbVie Presents Long-Term RINVOQ Data
Positive Sentiment: Recent regulatory and partnership activity is improving the investment narrative. Coverage points to FDA approval of JUVMO for Parkinson’s disease, along with new partnerships and research collaborations, as potential sources of future cash flow and diversification. Some analysis suggests ABBV could be undervalued if these assets perform successfully. AbbVie Stock May Be 41% Undervalued Following JUVMO Approval
Neutral Sentiment: Third-quarter results are the next major catalyst. AbbVie will report third-quarter 2026 results before the market opens on October 30, followed by an earnings call. Investors will look for continued momentum from Skyrizi, Rinvoq and neuroscience products. AbbVie to Host Third-Quarter 2026 Earnings Conference Call
Negative Sentiment: Valuation and patent-related risks may be limiting upside. ABBV has gained roughly 25% in six months and delivered a 187.5% five-year total return, leaving investors concerned that expectations are already high. Humira revenue erosion, competitive pressure and a reported P/E above 70 create a higher bar for additional gains. ABBV Stock Rises 25% in 6 Months

AbbVie Price Performance

AbbVie stock opened at $259.95 on Tuesday. The stock’s 50 day moving average price is $257.79 and its 200 day moving average price is $234.39. AbbVie has a 1-year low of $190.75 and a 1-year high of $269.39. The company has a market cap of $459.28 billion, a PE ratio of 73.43, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts anticipate that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AbbVie

Hedge funds have recently added to or reduced their stakes in the business. Burk Holdings LLC purchased a new position in shares of AbbVie during the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC grew its holdings in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares during the last quarter. Abound Financial LLC acquired a new stake in AbbVie during the 4th quarter valued at $32,000. Principia Wealth Advisory LLC increased its position in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Finally, Merkkuri Wealth Advisors LLC acquired a new position in shares of AbbVie in the first quarter worth $34,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

(Get Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.